Abstract

Background: Keloids are pathological scars characterized by nodular fibrous tissue that extends beyond the border of initial damage. These lesions do not spontaneously regress and can cause cosmetic disfigurements and functional disabilities. Intralesional Injection of Triamcinolone Acetonide (ILITA), alone or in combination with other therapy, is one of the first-line treatment modalities. In this study the authors evaluated the objective efficacy of ILITA treatment in keloids management using this new imaging system.

Materials and Methods: 37 patients with 45 keloid scars were treated with intralesional injection of triamcinolone acetonide (TAC) 20 mg/ml at an interval of three weeks. Antera3D® camera took the images and dates of the treated area in each patient, before the treatment (T0) and at three weeks after the last injection (T1). The system processed the levels of color, elevations, melanin and hemoglobin expression. All the scars were also evaluated, at the same times, by validated Vancouver Scar Scale (VSS). Comparison of the variables was performed using a Wilcoxon signed-rank test with a p < 0.05.

Results: At T0, mean VSS score was 8.67 ± 1.35 which reduced to 3.62 ± 1.72 at final follow up. Antera3D® scores were statistically significant differences in color (8.14 ± 2.41 vs 9.54 ± 1.81), protrusion (381.3 ± 15.6 vs 198.6 ± 21.3), melanin (0.53 ± 0.02 vs 0.62 ± 0.2) and hemoglobin (1.26 ± 0.41 vs 2.21 ± 0.41) expression levels after the treatment.

Conclusions: In our clinical trial, the data results demonstrated that ILITA seems to be effective in reducing keloid dimensions and symptoms such as itching and pain, even if the treatment has local minimal adverse effects such as pain, telangiectasias and atrophy.

Keywords
Keloid, triamcinolone acetonide, antera 3D, ILITA, scar, scar scales
Lay Summary

Keloids are pathological scars characterized by nodular fibrous tissue that extends beyond the border of initial damage. Large keloids can cause cosmetic disfigurements and functional disabilities that affect quality of life. In literature, several treatment approaches have been described but, to date, no single method is considered superior. The International Advisory Panel on Scar Management recommended the use of intralesional steroid injections for keloids treatment. The efficacy of treatment may be evaluated with subjective scale; as no one can guarantee an objective evaluation. To eliminate the observer and/or patient factors, and to obtain a reliable, consistent, feasible, valid and objective evaluation a skin analysis camera system called Antera3D® (Miravex, Dublin, Ireland) can be used.

In this study the authors evaluated the objective efficacy of triamcinolone acetonide treatment in keloids management using this imaging system. In this series, for Antera3D® scores there were statistically significant differences in color, protrusion, melanin and hemoglobin expression levels before and after treatment. The device directly shows the treatment changes, measured objectively and accurately, without bias of traditional evaluation scoring scale.

Antera3D® system guarantees an objective evaluation of effectiveness of scar treatment enabling clinicians to modulate the therapy according to the scores registered.

Introduction

Keloids are pathological scars characterized by nodular fibrous tissue that extends beyond the borders of the initial damage. These lesions do not regress spontaneously, but often have a long uninterrupted evolution and growth, and can recur following surgical excision. African, Asian and Latin ethnicities are more affected. The anatomical areas frequently afflicted are the chest, shoulders and earlobes. Symptoms that can occur include pain, itching, dysesthesia, and restricted movements. Large keloids can cause cosmetic disfigurements and functional disabilities that impact the quality of life (Figure 1).

Histological examination of keloid scars shows dense fibroblasts and bundles of collagen; the massive extracellular matrix deposition and fibroblasts proliferation (with lower apoptotic rate) result from the lack of control mechanisms during the “remodeling phase” of wound healing. However, the complete pathological mechanism has not been elucidated. Recent research indicates that the formation and growth of keloids are clearly associated with genetic, epigenetic, systemic and local risk factors.

In literature, several treatment approaches have been described but, to date, no single method is considered superior. There are many options available: occlusive dressings, compression, silicone sheets, intralosional injection of steroid or other drugs (verapamil, 5FU, interferon), cryotherapy, surgical excision, pulsed dye laser, radiotherapy, imiquimod cream and Adipose Derived Stem Cells (ADSCs). Non-surgical approach is recommended for primary treatment, because keloids have a high recurrence rate after surgical excision. The International Advisory Panel on Scar Management recommended the use of intralesional steroid injections for keloids treatment. IntraLesional Injection of Triamcinolone Acetonide (that we called ILITA treatment), alone or in combination with other therapy, is one of the first-line treatment modalities. The efficacy of triamcinolone acetonide in keloids treatment has been demonstrated in various clinical trials since 1960, with efficacy rate from 50 to 100%, and recurrence rate of 50% in five years.

Corticosteroids reduce collagen synthesis, inhibit rapid growth of fibroblasts (antimitotic effect), promote vasoconstriction (reducing the delivery of oxygen and nutrients to the wound bed) and control local inflammation (inhibiting leukocyte and monocyte migration and phagocytosis). Furthermore, they reduce protease inhibitors, alpha1antitrypsine, alpha2macroglobuline, TGF-beta, IGF1 and VEGF.

Triamcinolone acetonide is used in different concentrations (ranging from 10 to 40 mg/ml), frequency (the interval between successive injections ranges from one to four weeks), and length of treatment (number of injections may vary from four to eight).
ILITA therapy may induce adverse effects such as telangiectasias, atrophy, hypo/hyperpigmentation, ulcers, necrosis, and Cushing’s syndrome.13–20

The efficacy of treatment may be evaluated with subjective scales. In literature we identified 10 different scales: Vancouver Scar Scale (VSS), Dermatology Life Quality Index (DLQI), Manchester Scar Scale (MSS), Patient and Observer Scar Assessment Scale (PSAS/OSAS), Bock Quality of Life questionnaire (Bock QoL), Stony Brook Scar Evaluation Scale (SBSES), Patient-Reported Impact of Scars Measure (PRISM), Patient Scar Assessment Questionnaire (PSAQ), University of North Carolina “4P” Scar Scale (UNC4P) (Table 1).23 However, these scales do not guarantee an objective assessment because they are influenced by observer and/or patient factors. To obtain a reliable, consistent, feasible, valid and objective evaluation, we propose the use of a new skin analysis camera system called Antera3D® (Miravex, Dublin, Ireland). This 3D camera, using a light emitting diodes and a complex software, evaluates skin objective indicators (measuring dimensions, texture, and colors) and reconstructs 3D images.

In this study the authors evaluated the objective efficacy of ILITA treatment in keloids management using Antera3D® imaging system. To our knowledge, in literature there are no studies comparing the Antera3D® measurements with other methods for keloid evaluation such as VVS or P/OSAS. Our study is the first report of this comparison.

Materials and methods
This open clinical trial was carried out on 37 patients at the Department of Plastic Surgery of OORR Ospedali Riuniti –University of Foggia (Italy) from January 2018 to July 2019.

Inclusion criteria were: keloid scar never treated before, age>18 years. Exclusion criteria were: age<18 years, immunodepression, pregnancy, lactation, diabetes, local/general infection, previous or additional scar treatment, connective tissue disorders, hypersensitivity to lidocaine.

The study conformed to good clinical practice guidelines and followed the recommendations of the Declaration of Helsinki. The local Ethics Committee Comitato Etico (CE) of Azienda Ospedaliiero-Universitaria “Ospedali Riuniti” di Foggia approved the protocol; every

Figure 1. Large earlobe keloid of man after minimal trauma.
patient signed the informed consent of the treatment procedures and the adverse effects.

The authors treated a total of 37 patients with 45 keloid scars with intralesional injection of TAC 20 mg/ml at an interval of three weeks for a total of four sittings.

The investigators used an Antera3D® camera to take the images and dates of the treated area in each patient, before the treatment (T0) and at three weeks after the last injection (84 days from the first injection, T1). The Antera3D® system processed the levels of color, elevations, melanin and hemoglobin expression (Figures 2 and 3). All the scars were also evaluated, at the same time, by validated Vancouver Scar Scale (VSS) that assesses four variables: vascularity, thickness, pliability, and pigmentation.

During the study every consideration and adverse effects were signaled. Patients were followed-up with from 84 to a max of 168 days after first treatment. The study was planned as a case-series study to objectively evaluate the efficacy of TAC with respect to scar outcome using the Antera3D® system.

We present summary statistics as means with standard deviation (Std) and medians with a range for continuous variables. Comparison of the categorical variables pre- and post-treatment was performed using a Wilcoxon signed-rank test. An expert bio-statistician performed the statistical analysis using Statistical Package for Social

| Scales      | Total score | Domains (range scores)                                      | Items                                                                 |
|-------------|-------------|-------------------------------------------------------------|----------------------------------------------------------------------|
| VSS         | 0–13        | Physical characteristics (0–8)                              | Height, pliability                                                   |
|             |             | Esthetics (0–5)                                             | Vascularity, pigmentation                                            |
| DLQI        | 0–30        | QoL (0–30)                                                  | Symptoms and feelings, daily activities, leisure, personal relationships, work and school, treatment |
| MSS         | 0–28        | Physical characteristics (0–8)                              | Contour, texture                                                    |
|             |             | Esthetics (0–10)                                            | Color, distortion                                                   |
|             |             | Overall opinion (0–10)                                     |                                                                      |
| OSAS        | 0–60        | Physical characteristics (0–40)                             | Thickness, relief, pliability, surface area                          |
|             |             | Esthetics (0–20)                                            | Vascularity, pigmentation                                            |
| PSAS        | 0–60        | Symptoms (0–20)                                             | Pain, pruritus                                                      |
|             |             | Esthetics (0–10)                                            | Color                                                               |
|             |             | Physical characteristics (0–30)                             | Stiffness, thickness, irregularity                                   |
| Bock QoL    | 0–15        | QoL related to:                                             | Feeling of worthlessness, loss of physical attractiveness, sexual desirability, and avoiding public situations |
|             |             | Psychological impairment (0–9)                              | Mobility, symptoms                                                  |
|             |             | Physical impairment (0–5)                                   |                                                                      |
|             |             | The thought of committing suicide because of scars (0–1)     |                                                                      |
| SBSES       | 0–5         | Physical characteristics (0–2)                              | Width, height                                                       |
|             |             | Esthetics (0–3)                                             | Color, hatch marks, overall appearance                              |
| PSAQ        | NA          | Esthetics (9–36)                                            | Appearance                                                          |
|             |             | Scar-related self-consciousness (6–24)                      | Consciousness                                                       |
|             |             | Satisfaction with scar esthetics (8–32)                     | Satisfaction with appearance                                        |
|             |             | Satisfaction with symptoms (5–20)                           | Satisfaction with symptoms                                          |
| PRISM       | NA          | QoL (0–24)                                                  | QoL                                                                 |
|             |             | Symptoms (0–13)                                             |                                                                      |
| UNC4P       | 0–12        | Symptoms (0–12)                                             | pain, paresthesias, pruritus, and pliability                          |
Figure 2. Antera 3D® analysis of keloid developed after a skin infection (pimple); (a) dimensions; (b) protrusion; (c) melanin; (d) hemoglobin.

Figure 3. Antera 3D® analysis of keloid pre- and post-treatment (a) dimensions; (b) protrusion; (c) melanin; (d) hemoglobin.
| ID | Sex | Etiology       | Age | Site                 | Numbers of keloids | Duration (Months) |
|----|-----|----------------|-----|----------------------|--------------------|------------------|
| 1  | F   | BURN           | 27  | SHOULDER             | 1                  | 4                |
| 2  | M   | BURN           | 18  | CHEST                | 1                  | 2                |
| 3  | M   | SURGICAL       | 31  | EAR                  | 1                  | 1                |
| 4  | M   | SURGICAL       | 25  | CHEST                | 1                  | 3                |
| 5  | F   | BURN           | 29  | SHOULDER             | 1                  | 1                |
| 6  | M   | POST-INFECTION | 21  | EAR                  | 1                  | 36               |
| 7  | M   | BURN           | 33  | CHEST-SHOULDER       | 2                  | 21               |
| 8  | F   | BURN           | 32  | CHEST                | 1                  | 1                |
| 9  | M   | BURN           | 30  | SHOULDER             | 1                  | 6                |
| 10 | M   | POST-INFECTION | 29  | CHEST                | 1                  | 3                |
| 11 | M   | SURGICAL       | 22  | CHEST                | 1                  | 2                |
| 12 | M   | BURN           | 19  | CHEST-NECK-SHOULDER  | 3                  | 13               |
| 13 | F   | SURGICAL       | 41  | CHEST                | 1                  | 10               |
| 14 | M   | SURGICAL       | 36  | CHEST                | 1                  | 7                |
| 15 | M   | POST-INFECTION | 31  | EAR                  | 1                  | 2                |
| 16 | F   | SURGICAL       | 30  | CHEST                | 1                  | 4                |
| 17 | F   | BURN           | 27  | CHEST-SHOULDER       | 2                  | 8                |
| 18 | M   | BURN           | 26  | CHEST                | 1                  | 3                |
| 19 | M   | BURN           | 28  | SHOULDER             | 1                  | 2                |
| 20 | F   | SURGICAL       | 29  | CHEST                | 1                  | 16               |
| 21 | M   | SURGICAL       | 35  | CHEST                | 1                  | 4                |
| 22 | M   | POST-TRAUMA    | 40  | CHEST                | 1                  | 3                |
| 23 | M   | BURN           | 29  | CHEST-NECK-SHOULDER  | 3                  | 4                |
| 24 | M   | BURN           | 26  | CHEST                | 1                  | 7                |
| 25 | M   | SURGICAL       | 25  | SHOULDER             | 1                  | 3                |
| 26 | M   | BURN           | 30  | CHEST                | 1                  | 9                |
| 27 | F   | POST-INFECTION | 28  | EAR                  | 1                  | 6                |
| 28 | M   | SURGICAL       | 47  | CHEST                | 1                  | 12               |
| 29 | M   | POST-TRAUMA    | 40  | CHEST                | 1                  | 4                |
| 30 | M   | BURN           | 36  | CHEST-SHOULDER       | 2                  | 10               |
| 31 | F   | BURN           | 27  | CHEST                | 1                  | 2                |
| 32 | M   | POST TRAUMA    | 22  | CHEST                | 1                  | 3                |

(Continued)
A p value of less than 0.05 was considered statistically significant.

### Results

A total of 37 patients were treated with ILITA 20 mg/ml. All completed the sessions, and there were no dropouts. There were 27 (73%) male participants and 10 (27%) female, and the mean age was 29.5 ± 10.4 years (range 18–47). 31 patients (83.8%) had one keloid; six (16.2%) had two or more keloids, with a total of 45 keloids treated. Duration of keloid ranged from one to 36 months with a median of four months.

Scar locations were: chest 27 (60%), shoulder 11 (24.4%), ear 4 (9%), neck 2 (4.4%), thigh/leg 1 (2.2%). See Table 2.

An assessment of VSS score was carried out at the baseline (T0, before the treatment) and at three weeks after the last injection (T1, at 12 weeks after the first treatment). At T0, mean VSS score was 8.67 ± 1.35 (median 8.0) which decreased to 3.62 ± 1.72 (median 3.0) at the final follow up, showing a mean change of −5.05 ± 1.41. On evaluating the data, it was found to be statistically significant (z is 4.325; p-value = 0.025). See Table 3.

Patients reported these adverse effects: pain in 13 cases (35.1%), telangiectasia in three cases (8.1%), atrophy/hypopigmentation in two (5.4%).

The Antera3D® score (see Table 4):

1. For COLOR after four sessions of ILITA were 8.14 ± 2.41, which were significantly lower than before the treatment (9.54 ± 1.81, z = 3.216, p-value <0.05).
2. For LARGE ELEVATIONS after four sessions of ILITA were 198.6 ± 21.3, which were significantly lower than before the treatment (381.3 ± 15.6, z = 2.635, p-value <0.05).
3. For MELANIN after four sessions of ILITA were 0.53 ± 0.02, which were significantly lower than before the treatment (0.62 ± 0.2, z = 2.4, p-value <0.05).
4. For HEMOGLOBIN after four sessions of ILITA were 1.26 ± 0.41, which were significantly lower than before the treatment (2.21 ± 0.41, z = 2.09, p-value <0.05).

### Discussion

Nowadays, there is no gold standard treatment for keloids. Combined therapies are more successful than one alone: in fact, ILITA, alone or in combination with other drugs (5-FU, verapamil, bleomycin), radiation therapy or laser or after surgical excision, is an optimal non-surgical approach. It reduces scar dimensions and symptoms such as pain and itching, and it prevents recurrence. The action mechanism is multiple: reducing collagen and Glycosaminoglycans (GAGs) synthesis, inhibiting fibroblast growth, enhancing fibroblast degeneration, and having anti-inflammatory effects.

The evaluation of therapeutic effectiveness on scars is often made with subjective evaluation (patient/surgeon) using clinic scales (i.e., VSS, DLQI, MSS, P/OSAS, UNC4P, etc.). These scales are simple but no single one had been shown to be reliable, consistent, feasible, and valid at the same time because they are subjective to bias, lack of objectivity and repeatability of measure. So, an objective and independent assessment is needed. Antera3D® is a validated new tool for the objective evaluation of skin characteristics and, therefore, of the scars.

It is a new device, developed in the Department of Physics of Trinity College in Dublin, which contains a camera for image acquisition of 56*56 mm (3136 mm²) and a computer with a software for analysis of the acquired image data. This novel 3D camera system collects the
reflections after irradiation of the skin with a multi-spectrum light emitted from different directions by seven different wavelengths LED (light-emitting diodes).

With the spatial and spectral analysis of the different reflections and optical penetration lengths of different waves, a digital processing of the lights signals reconstructs the skin surface in two and three dimensions and allows evaluation of the skin topography and the chromophores’ concentration. Therefore, it can be used to evaluate skin color, texture, pore, depression wrinkle, elevation, melanin, hemoglobin and lesions.\textsuperscript{24,25}

The reconstruction of the skin texture is achieved using a technique based on Shape from Shading (SFS), modified to improve accuracy and to eliminate skin glare. Moreover, the device uses seven different wavelengths of LED light (entire visible spectrum) to acquire the reflectance data which are transformed into skin absorption coefficients and used to quantify melanin and hemoglobin concentrations, using mathematical correlation with known spectral absorption data of these chromophores.\textsuperscript{26,27} The skin surface shape is used to compensate for light intensity variation due to the varying direction of incident light.

The images acquired are independent of lighting conditions, using a combination of polarizing filters and a software, which guarantees reproducible conditions and accuracy of the results.

| ID | VSS T0 | VSS T1 |
|----|--------|--------|
| 1  | 8      | 4      |
| 2  | 7      | 3      |
| 3  | 6      | 2      |
| 4  | 8      | 4      |
| 5  | 8      | 4      |
| 6  | 6      | 2      |
| 7  | 9      | 5      |
| 8  | 7      | 3      |
| 9  | 8      | 4      |
| 10 | 7      | 3      |
| 11 | 9      | 4      |
| 12 | 9      | 5      |
| 13 | 8      | 4      |
| 14 | 8      | 3      |
| 15 | 6      | 3      |
| 16 | 9      | 5      |
| 17 | 8      | 5      |
| 18 | 7      | 4      |
| 19 | 7      | 3      |
| 20 | 8      | 4      |
| 21 | 7      | 3      |
| 22 | 8      | 4      |
| 23 | 9      | 6      |
| 24 | 8      | 4      |
| 25 | 9      | 6      |
| 26 | 7      | 3      |
| 27 | 6      | 3      |
| 28 | 8      | 4      |
| 29 | 7      | 4      |
| 30 | 9      | 5      |
| 31 | 8      | 4      |
| 32 | 8      | 3      |
| 33 | 9      | 5      |

(Continued)
Table 4. Antera3D scores before and after treatment.

| ID | Color before | after | Elevation before | after | Melanin before | after | Hemoglobin before | after |
|----|--------------|-------|------------------|-------|---------------|-------|-------------------|-------|
| 1  | 9.54         | 8.14  | 381.3            | 198.6 | 0.62          | 0.53  | 2.21              | 1.26  |
| 2  | 9.78         | 8.36  | 411.4            | 206.3 | 0.68          | 0.59  | 2.56              | 1.81  |
| 3  | 10.02        | 9.11  | 442.3            | 231.6 | 0.81          | 0.73  | 3.21              | 2.11  |
| 4  | 9.88         | 8.74  | 420.6            | 217.7 | 0.74          | 0.67  | 2.92              | 1.82  |
| 5  | 9.33         | 8.01  | 353.9            | 178.3 | 0.60          | 0.49  | 2.15              | 1.12  |
| 6  | 9.11         | 7.98  | 323.6            | 155.9 | 0.58          | 0.48  | 1.98              | 0.87  |
| 7  | 9.67         | 8.17  | 389.2            | 199.5 | 0.71          | 0.54  | 2.85              | 1.74  |
| 8  | 9.82         | 8.22  | 425.5            | 266.2 | 0.75          | 0.59  | 2.92              | 1.81  |
| 9  | 10.06        | 8.54  | 439.7            | 287.1 | 0.81          | 0.64  | 3.11              | 1.97  |
| 10 | 9.65         | 8.36  | 397.8            | 208.7 | 0.65          | 0.53  | 2.32              | 1.20  |
| 11 | 9.71         | 8.29  | 415.1            | 211.2 | 0.69          | 0.60  | 2.54              | 1.43  |
| 12 | 9.47         | 8.03  | 377.7            | 188.7 | 0.59          | 0.47  | 2.01              | 0.96  |
| 13 | 9.56         | 8.11  | 384.6            | 196.2 | 0.63          | 0.55  | 2.41              | 1.31  |
| 14 | 9.85         | 8.37  | 431.3            | 236.8 | 0.74          | 0.62  | 2.88              | 1.71  |
| 15 | 9.77         | 8.21  | 399.8            | 258.7 | 0.68          | 0.59  | 2.57              | 1.42  |
| 16 | 9.13         | 7.82  | 341.8            | 187.6 | 0.55          | 0.41  | 2.09              | 1.03  |
| 17 | 9.04         | 7.85  | 339.7            | 178.3 | 0.47          | 0.39  | 1.91              | 0.89  |
| 18 | 9.76         | 8.33  | 386.2            | 197.6 | 0.69          | 0.53  | 2.61              | 1.54  |
| 19 | 10.11        | 8.57  | 447.6            | 285.8 | 0.81          | 0.71  | 3.15              | 1.96  |
| 20 | 8.81         | 7.54  | 298.3            | 177.4 | 0.39          | 0.28  | 1.43              | 0.67  |
| 21 | 9.53         | 8.12  | 378.2            | 199.1 | 0.62          | 0.51  | 2.18              | 1.74  |
| 22 | 9.68         | 8.22  | 387.5            | 200.3 | 0.65          | 0.55  | 2.33              | 1.81  |
| 23 | 9.72         | 8.35  | 391.4            | 210.4 | 0.66          | 0.57  | 2.47              | 1.32  |
| 24 | 9.81         | 8.41  | 401.3            | 214.9 | 0.74          | 0.63  | 2.85              | 1.51  |
| 25 | 8.96         | 7.83  | 314.8            | 112.8 | 0.48          | 0.29  | 1.98              | 0.69  |
| 26 | 9.10         | 7.77  | 336.9            | 131.8 | 0.51          | 0.42  | 2.12              | 1.17  |
| 27 | 9.54         | 8.13  | 356.8            | 174.6 | 0.63          | 0.53  | 2.33              | 1.98  |
| 28 | 9.49         | 8.01  | 357.7            | 178.4 | 0.61          | 0.50  | 2.42              | 1.88  |
| 29 | 9.69         | 8.43  | 389.1            | 198.5 | 0.72          | 0.66  | 2.69              | 2.12  |
| 30 | 8.88         | 7.41  | 313.8            | 186.3 | 0.58          | 0.49  | 1.88              | 1.02  |
| 31 | 9.56         | 8.21  | 393.7            | 203.5 | 0.62          | 0.52  | 2.20              | 1.15  |
| 32 | 9.74         | 8.53  | 422.9            | 221.8 | 0.67          | 0.56  | 2.51              | 1.44  |

(Continued)
The analysis of melanin and hemoglobin are important for more skin lesions, such as benign and malign cancers, precancerosis, rosacea, vitiligo, port wine stains, melasma, scars, etc.

In particular, the measurement of melanin and hemoglobin concentrations is relevant in analyzing the properties of keloid scars because: hemoglobin is contained in blood vessels of papillary dermis that are hyperexpressed in these pathologic scars, because of neoangiogenesis and local inflammation\(^5,28\); and because melanin, produced by melanocytes, has a duplex rule in keloid formation. In fact, it causes a decreasing of histological pH which inhibits collagenase that disrupts collagen degradation process; moreover, during wound healing, melanocytes from the stratum basal interact with dermal fibroblast facilitating fibroblast proliferation and secretion/deposition of collagen\(^29,30\).

So, the reduction of melanin and hemoglobin concentrations after the treatment is indicative of the improvement of the clinical status of scar and of the efficacy of therapy.

Antera3D® is a great support to the diagnostic evaluation for the following reasons:

- It is an objective method because it responds to sophisticated mathematical software for spectrometric conversion of the light and converts all possible skin parameters, except for the tactile property, into numbers; there is no subjective bias of evaluation with clinic scales.
- It allows comparison pre- and post-therapeutic treatment images.
- It is an operator-independent system. It is possible to catch the image at a specific capture rate (preferable > 98%); if there are problems relating to the centering of the image, a specific function helps to correct any possible error.
- It is possible to repeat the analysis any time and without limitation.
- It is safe and intuitive (very short learning curve is necessary).

In our series, for Antera3D® scores there were statistically significant differences in color, protrusion, melanin and hemoglobin expression levels, before and after treatment with triamcinolone acetonide. The device directly shows the treatment changes, measured objectively and accurately, without bias of traditional evaluation scoring scales.

Thanks to the three-dimensional multispectral analysis performed with Antera 3D®, data of this study revealed an improvement of the

| ID | Color before after | Elevation before after | Melanin before after | Hemoglobin before after |
|----|--------------------|------------------------|----------------------|------------------------|
| 33 | 9.21               | 7.89                   | 415.5                | 217.2                  |
| 34 | 9.58               | 8.13                   | 436.8                | 235.9                  |
| 35 | 9.13               | 7.81                   | 401.2                | 211.8                  |
| 36 | 9.96               | 8.22                   | 445.5                | 241.4                  |
| 37 | 9.52               | 8.11                   | 380.8                | 198.2                  |
| 38 | 8.93               | 7.74                   | 290.6                | 185.1                  |
| 39 | 9.51               | 8.09                   | 383.2                | 199.6                  |
| 40 | 9.62               | 8.26                   | 393.6                | 216.9                  |
| 41 | 9.58               | 8.15                   | 385.7                | 201.3                  |
| 42 | 10.08              | 9.09                   | 441.2                | 247.3                  |
| 43 | 9.44               | 8.06                   | 348.8                | 178.7                  |
| 44 | 9.47               | 8.11                   | 356.3                | 187.4                  |
| 45 | 9.54               | 8.09                   | 363.8                | 189.5                  |

Table 4. (Continued)
aesthetic-functional outcomes in a clearer and more objective way.

Moreover, this type of analysis would allow the clinician to modify the treatment plan according to the changes of these indexes after the therapy, obtaining a better result.

The limitation in our study is its small simple size; in fact, though Antera3D® is able to define a standard treatment/therapeutic success through specific parameters and scores, its major limit is the need for several clinical cases to reach standardization. Therefore, further research using Antera3D® is needed; we are consequently collecting and analyzing other data in order to expand this clinical trial in future and produce a stronger study.

Furthermore, our participants were followed-up with for maximum of 168 days after the first treatment, but as keloids tend to relapse, an extended follow-up is needed.

Conclusions

In our clinical trial, the data results demonstrated that ILITA seems to be effective in reducing keloid dimensions and symptoms such as itching and pain, even if the treatment has local minimal adverse effects such as pain, telangiectasias and atrophy.

This camera analysis system guarantees an objective evaluation of scar treatment effectiveness; so clinicians can modify the therapy according to the scores registered. It is worth promoting widely because it is easy to use, safe, objective, repeatable, with low cost, and helpful to measure in clinical studies the efficacy of treatment, even with a long follow-up.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Fedele Lembo https://orcid.org/0000-0003-0782-6406

References

1. Robles DT and Berg D. Abnormal wound healing: keloids. Clin Dermatol 2007; 25: 26–32.
2. Jumper N, Paus R and Bayat A. Functional histopathology of keloid disease. Histol Histopathol 2015; 30: 1033–1057.
3. Ogawa R. Recent advances in scar biology. Int J Mol Sci 2018; 19: 1749.
4. Salem A, Assaf M, Helmy A, et al. Role of vascular endothelial growth factor in keloids: A clinicopathologic study. Int J Dermatol 2009; 48: 1071–1077.
5. Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci 2017; 18: 606.
6. Tsai CH and Ogawa R. Keloid research: Current status and future direction. Scars, Burns & Healing 2019; 5: 209531319806659.
7. Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560–571.
8. Lee HJ and Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci 2018; 19: 711.
9. Ogawa R, Akaishi S, Kuribayashi S, et al. Keloids and hypertrophic scars can now be cured completely: Recent progress in our understanding of the pathogenesis of keloids and hypertrophic scars and the most promising current therapeutic strategy. J Nippon Med Sch 2016; 83: 46–53.
10. Lembo F, Parisi D, Annacontini L, et al. Pulsed dye laser and corticosteroids: A combined protocol for keloid management. Lasers Med Sci 2012; 27: 849–893.
11. Lembo F, Parisi D, Annacontini L, et al. The efficacy of adipose-derived adult stem cells (ADSC) in improving the evolution of scars. J Tissue Eng Regen Med 2012; 6: 1–429.
12. Lembo F, Parisi D and Portincasa A. Efficacy of adipose-derived adult stem cells in improving the evolution of post traumatic or surgical scars. Plast Reconstr Surg 2013; 132: 501.
13. Morelli Coppola M, Salillo R, Segreto F, et al. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol 2018; 11: 387–396.
14. Hietanen KE, Järvinen TA, Huhtala H, et al. Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections – a randomized controlled trial. JPRAS 2019; 72: 4–11.
15. Saki N, Mohkhtari R and Nozari F. Comparing the efficacy of intralesional triamcinolone acetonide with verapamil in treatment of keloids: A randomized controlled trial. Dermatol Pract Concept 2019; 9: 4–9.
16. Hietanen K, Välsuo P, Kuokkanen H, et al. Long-term results of intralesional triamcinolone acetonide injections in keloid treatment. J Clin Trials 2016; 6: 4.
17. Kant SB, van den Kerckhove E, Colla C, et al. A new treatment of hypertrophic and keloid scars with combined triamcinolone and verapamil: A retrospective study. Eur J Plast Surg 2018; 41: 69–80.
18. Garg AM, Shah YM, Garg A, et al. The efficacy of intralesional triamcinolone acetonide (20mg/ml) in the treatment of keloid. Int Surg J 2018; 5: 868–872.
19. Trisdiana Perdanasari A, Torresetti M, Grassetti L, et al. Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burn Trauma 2015; 3: 14.
20. Muneuchi G, Suzuki S, Onodera M, et al. Long-term outcome of intralesional injection of triamcinolone acetonide for the treatment of keloid scars in Asian patients. Scand J Plast Reconstr Surg Hand Surg 2006; 40: 111–116.
21. Wong TS, Li JZ-H, Chen S, et al. The efficacy of triamcinolone acetonide in keloid treatment: A systematic review and meta-analysis. Front Med 2016; 3: 71.
22. Rosses C and Téot L. The use of corticosteroids to treat keloids: a review. Int J Low Extrem Wounds 2008; 7: 137–145.
23. Vercelli S, Ferriero G, Sartorio F, et al. How to assess postsurgical scars: A review of outcome measures, Disabil Rehabil 2009; 31: 2055–2065.
24. Zhang N, Shi K, Hong L, et al. Antera 3D camera: A novel method for evaluating the therapeutic efficacy of fractional CO2 laser for surgical incision scars. *J Cosmet Dermatol* 2018; 17: 1041–1045.

25. Matias AR, Ferreira M, Costa P, et al. Skin colour, skin redness and melanin biometric measurements: comparison study between antera® 3D, mexameter® and colorimeter®. *Skin Res Technol* 2015; 21: 346–362.

26. Cantisani C, Paolino G, Pellacani G, et al. MAL Daylight photodynamic therapy for actinic keratosis: Clinical and imaging evaluation by 3D camera. *Int J Mol Sci* 2016; 17: 1108.

27. Tretti Clementoni M and Lavagno R. A novel 1565 nm nonablative fractional device for stretch marks: a preliminary report. *J Cosmet Laser Ther* 2015; 17: 148–155.

28. Tseng SH, Hsu CK, Yu-Yun Lee J, et al. Noninvasive evaluation of collagen and hemoglobin contents and scattering property of in vivo keloid scars and normal skin using diffuse reflectance spectroscopy: pilot study. *J Biomed Opt* 2012; 17: 077005.

29. Wihastyoko HYL, Perdanakusuma DS, Soeharto S, et al. Correlation of melanin content with collagen density in keloid patients. *Open Access Maced J Med Sci* 2021; 9: 265–271.

30. Gao FL, Jin R, Zhang L, et al. The contribution of melanocytes to pathological scar formation during wound healing. *Int J Clin Exp Med* 2013; 6: 609–613.

How to cite this article
Lembo F, Cecchino LR, Parisi D and Portincasa A. The objective evaluation of triamcinolone acetonide efficacy in keloids management using Antera3D® imaging system. *Scars, Burns & Healing*, Volume 8, 2022. DOI: 10.1177/20595131221137768.